Teneligliptin

Overview

Chemical structure of Teneligliptin

Teneligliptin is an oral antidiabetic medication used in the management of type 2 diabetes mellitus. It belongs to the class of drugs known as DPP-4 inhibitors, which work by increasing the levels of incretin hormones, thereby enhancing the body's ability to lower blood glucose levels.

Mechanism of Action

Teneligliptin functions by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). This enzyme is responsible for the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By inhibiting DPP-4, teneligliptin prolongs the action of these hormones, leading to increased insulin secretion and decreased glucagon release in a glucose-dependent manner.

Pharmacokinetics

Teneligliptin is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. It has a half-life of approximately 24 hours, allowing for once-daily dosing. The drug is primarily metabolized in the liver and excreted via the kidneys.

Clinical Use

Teneligliptin is indicated for the treatment of type 2 diabetes mellitus in adults. It is often used in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin to achieve better glycemic control.

Side Effects

Common side effects of teneligliptin include nasopharyngitis, headache, and hypoglycemia when used in combination with other antidiabetic medications. Rare but serious side effects may include pancreatitis and allergic reactions.

Contraindications

Teneligliptin is contraindicated in patients with a history of hypersensitivity to the drug or any of its components. Caution is advised in patients with severe renal impairment or hepatic impairment.

Related pages

• Type 2 diabetes mellitus
• DPP-4 inhibitors
• Metformin
• Insulin